<p><strong>Sonoma Pharmaceuticals</strong> (NASDAQ:SNOA) shares are down during Monday’s session.</p>



<p>On Friday, the company priced its public offering aimed at raising approximately $4 million, sending shares lower.</p>



<h2>Sonoma Pharmaceuticals Prices Public Offering</h2>



<p>Sonoma Pharmaceuticals has priced its public offering at $1.35 per share, consisting of nearly 2.96 million shares and the same number of warrants. </p>



<p>The offering is expected to close on April 27, 2026, and the proceeds will be used for general corporate purposes, including working capital.</p>



<div>


<p>
<strong>
Read Also:

AtaiBeckley: Anxiety Drug Cuts Social Phobia Symptoms By 38%
</strong>
</p>


</div>


<h2>Retail Expansion With HOCl-Based Burn Relief Product</h2>



<p>In March, the dermatology and wound care company announced the U.S. retail launch of its advanced HOCl-based burn relief hydrogel in CVS and Walmart stores nationwide.</p>



<p>The hydrogel is indicated for the management of minor burns and skin irritations.</p>



<p>The launch represents Sonoma’s first large-scale consumer-focused burn relief product, building on the company’s established presence in professional healthcare settings, where its HOCl-based solutions have long been used in advanced wound and burn care protocols.</p>



<p>The product is being commercialized through one of Sonoma’s U.S.-based partners that distributes through CVS and Walmart, in line with the company’s strategy to leverage strategic partnerships to expand its presence across major retail channels.</p>



<h2>SNOA Technical Analysis: Trend, RSI And Key Levels</h2>



<p>Sonoma Pharmaceuticals is currently trading 49.3% below its 20-day simple moving average (SMA) and 62.2% below its 100-day SMA, indicating a bearish trend in the short to intermediate term. </p>



<p>The stock’s position within the 52-week range, between a high of $6.92 and a low of 85 cents, suggests significant downward pressure, as it is currently closer to its low.</p>



<p>The relative strength index (RSI) is at 26.92, indicating that the stock is oversold, which may suggest a potential for a price rebound if buying interest increases. </p>



<p>The moving average convergence divergence (MACD) is below the signal line, reinforcing the bearish momentum, as traders watch for any signs of a reversal.</p>



<ul>
<li><strong>Key Resistance</strong>: $2.00 — A level where selling pressure may increase.</li>



<li><strong>Key Support</strong>: 85 cents — The recent 52-week low, a critical level for buyers to defend.</li>
</ul>



<p><strong>SNOA Price Action:</strong> Sonoma Pharmaceuticals shares were down 1.75% at $1.12 at the time of publication on Monday, according to Benzinga Pro data.</p>



<p><em>Photo by Thapana_Studio via Shutterstock</em></p>



<div>


<p><strong>
Read Also:

Domino's Hit By Budget-Conscious Diners, Shares Tumble
</strong></p>


</div>

SNOA

<p>Sonoma Pharmaceuticals (SNOA) shares fell 1.75% to $1.12 following a $4M public offering priced at $1.35 per share. The offering, consisting of nearly 2.96 million shares and warrants, is set to close on April 27, 2026, with proceeds aimed at general corporate purposes. The stock is currently trading significantly below its moving averages, indicating a bearish trend, and is near its 52-week low of 85 cents. The relative strength index suggests the stock is oversold, potentially indicating a future price rebound if buying interest increases.</p>

What's Going On With Sonoma Pharma Stock Monday?